港股異動 | 海吉亞醫療(6078.HK)漲逾9%創新高 收購賀州廣濟醫院獲機構看好
格隆匯5月28日丨海吉亞醫療(6078.HK)股價高位震盪,最高見84.1港元創歷史新高,現報81.45港元,漲幅9.18%,最新總市值503.4億港元。野村東方國際證券指,5月26日海吉亞宣佈收購賀州廣濟醫院99%的股權。伽瑪星科技(海吉亞全資控股的子公司)和海吉亞醫院管理將分別持有該醫院70%和29%的股權,使其成為海吉亞的間接非全資子公司。除了70%的目標醫院淨利潤直接併入海吉亞的財務報表外,海吉亞醫院管理將向伽瑪星科技支付賀州廣濟醫院可分配淨利潤的29%作為醫院管理服務費,確保上市公司能夠取得收購醫院產生的經濟利益。給予海吉亞醫療增持評級 目標價101.70港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.